Literature DB >> 12427153

Hospitalized avascular necrosis after renal transplantation in the United States.

Kevin C Abbott1, Robert J Oglesby, Lawrence Y Agodoa.   

Abstract

BACKGROUND: The national incidence of and risk factors for hospitalized avascular necrosis (AVN) in renal transplant recipients has not been reported.
METHODS: This historical cohort study consisted of 42,096 renal transplant recipients enrolled in the United States Renal Data System (USRDS) between 1 July 1994 and 30 June 1998. The data source was USRDS files through May 2000. Associations with hospitalizations for a primary diagnosis of AVN (ICD-9 codes 733.4x) within three years after renal transplant were assessed in an intention-to-treat design by Cox regression analysis.
RESULTS: Recipients had a cumulative incidence of 7.1 episodes/1000 person-years from 1994 to 1998. The two-year incidence of AVN did not change significantly over time. Eighty-nine percent of the cases of AVN were due to AVN of the hip (733.42) and 60.2% of patients with AVN underwent total hip arthroplasty (THA); these percentages did not change significantly over time. In the Cox regression analysis, an earlier year of transplant, African American race [adjusted hazard ratio (AHR), 1.65, 95% confidence interval (CI) 1.33 to 2.03], allograft rejection (AHR 1.67, 95% CI 1.35 to 2.07), peritoneal dialysis (vs. hemodialysis; AHR 1.44, 95% CI 1.15 to 1.81), and diabetes (AHR 0.41, 95% CI 0.27 to 0.64) were the only factors independently associated with hospitalizations for AVN.
CONCLUSIONS: The incidence of AVN did not decline significantly over time in the renal transplant population. Patients with allograft rejection, African American race, peritoneal dialysis and earlier date of transplant were at the highest risk of AVN, while diabetic recipients were at a decreased risk.

Entities:  

Mesh:

Year:  2002        PMID: 12427153     DOI: 10.1046/j.1523-1755.2002.00667.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Opioid Prescription, Morbidity, and Mortality in US Transplant Recipients.

Authors:  Kevin C Abbott; Chyng-Wen Fwu; Paul W Eggers; Anne W Eggers; Prudence P Kline; Paul L Kimmel
Journal:  Transplantation       Date:  2018-06       Impact factor: 4.939

Review 2.  Metabolic bone diseases in kidney transplant recipients.

Authors:  Rubin Zhang; Kanwaljit K Chouhan
Journal:  World J Nephrol       Date:  2012-10-06

Review 3.  Aftercare for patients with transplanted organs.

Authors:  Harald Schrem; Hannelore Barg-Hock; Christian P Strassburg; Anke Schwarz; Jürgen Klempnauer
Journal:  Dtsch Arztebl Int       Date:  2009-02-27       Impact factor: 5.594

4.  Incidence and predictors of osteonecrosis among cyclosporin- or tacrolimus-treated renal allograft recipients.

Authors:  Masaki Takao; Takashi Sakai; Takashi Nishii; Hideki Yoshikawa; Shiro Takahara; Nobuhiko Sugano
Journal:  Rheumatol Int       Date:  2009-10-28       Impact factor: 2.631

5.  A case of avascular necrosis of the femoral head as initial presentation of chronic myelogenous leukemia.

Authors:  Ji Yong Moon; Byung Su Kim; Hye Ryeon Yun; Jung Hye Choi; Young Yul Lee; In Soon Kim; Myung Ju Ahn
Journal:  Korean J Intern Med       Date:  2005-09       Impact factor: 2.884

6.  Transitional changes in the incidence of hip osteonecrosis among renal transplant recipients.

Authors:  Masaki Takao; Hirohito Abe; Takashi Sakai; Hidetoshi Hamada; Shiro Takahara; Nobuhiko Sugano
Journal:  J Orthop Sci       Date:  2019-07-04       Impact factor: 1.601

7.  Comparison of total joint arthroplasty outcomes between renal transplant patients and dialysis patients-a meta-analysis and systematic review.

Authors:  Jiayi Li; Mingyang Li; Bo-Qiang Peng; Rong Luo; Quan Chen; Xin Huang
Journal:  J Orthop Surg Res       Date:  2020-12-09       Impact factor: 2.359

8.  Risk factors for symptomatic Avascular Necrosis (AVN) in a multi-ethnic Systemic Lupus Erythematosus (SLE) cohort.

Authors:  Syahrul Sazliyana Shaharir; Siew Huoy Chua; Rozita Mohd; Ruslinda Mustafar; Malehah Mohd Noh; Nor Shuhaila Shahril; Mohd Shahrir Mohamed Said; Sakthiswary Rajalingham
Journal:  PLoS One       Date:  2021-03-19       Impact factor: 3.240

Review 9.  Bone Marrow Multipotent Mesenchymal Stromal Cells as Autologous Therapy for Osteonecrosis: Effects of Age and Underlying Causes.

Authors:  Jehan J El-Jawhari; Payal Ganguly; Elena Jones; Peter V Giannoudis
Journal:  Bioengineering (Basel)       Date:  2021-05-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.